Development of gene expression inhibitors for the treatment of cutaneous carcinomas [0.03%]
用于治疗皮肤癌的基因表达抑制剂的研发
Dhruv Sharma,Aniruddha Roy,Gautam Singhvi
Dhruv Sharma
Antibiotics and non-traditional antimicrobial agents for pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials [0.03%]
临床一期、二期和三期用于治疗铜绿假单胞菌的抗生素及非传统抗菌剂
Laura T Romanos,Dimitrios S Kontogiannis,Chara Tsiampali et al.
Laura T Romanos et al.
Introduction: Multidrug-resistant Pseudomonas aeruginosa infections have disseminated globally and are associated with high mortality due to the considerable virulence of the pathogen and the limited therapeutic options. ...
David S Liebeskind
David S Liebeskind
Polyvalent immunoglobulin therapy: preclinical evidence and potential for treating chemotherapy-induced peripheral neuropathy [0.03%]
多价免疫球蛋白治疗：前期证据及其治疗化疗诱导的外周神经病变的潜力
William Moret,Aurore Danigo,Simon Frachet et al.
William Moret et al.
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often debilitating complication of cancer treatment, affecting over 68% of treated patients. This condition is characterized by sensory de...
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as a mechanistically informed therapeutic treatment for mania, mixed features and cognitive deficits in bipolar disorder? [0.03%]
胆碱和毒蕈碱受体在双相情感障碍中的作用：Xanomeoline-trospium氯化物和其他正在研究的毒蕈碱激动剂是否可以作为治疗双相情感障碍躁狂、混合特征和认知缺陷的有效且机制明确的治疗方法？
Roger S McIntyre
Roger S McIntyre
Introduction: Xanomeline-trospium chloride (Cobenfy, KarXT) received FDA approval on 26 September 2024, for the treatment of adults with schizophrenia. Xanomeline-trospium chloride is the first muscarinic M1, M4 acetylcho...
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment [0.03%]
BI 764198/TRP6053的I期临床试验：在健康志愿者和肾功能不全患者中的药代动力学、安全性及耐受性研究
Armin Schultz,Atef Halabi,Friedeborg Seitz et al.
Armin Schultz et al.
Background: BI 764198 could reduce podocyte injury in focal segmental glomerulosclerosis (FSGS). Research design and methods: Four Phas...
Treating KRAS G12C lung cancer: therapeutic potential of investigation drugs in early clinical study [0.03%]
治疗KRAS G12C肺癌：早期临床研究药物的治疗潜力调查
Kendra Wilson,Jesus Salvador Flores Banda,Fatima Raza et al.
Kendra Wilson et al.
Introduction: The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene is recognized as the most frequently mutated oncogene in advanced non-small cell lung cancer (NSCLC). The most prevalent mutation within this gene i...
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review [0.03%]
靶向GPRC5D治疗多发性骨髓瘤的新兴疗法：综合述评
Darren Pan,Anupama Kumar,Jodi J Lipof et al.
Darren Pan et al.
Introduction: GPRC5D is a promising myeloma-associated antigen, and several GPRC5D-targeted therapies are under active investigation, including CAR T cells, bispecific and trispecific antibodies, and antibody-drug conjuga...
A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development [0.03%]
血管内皮生长因子基因治疗缺血性心脏病的研究进展及临床开发评估
Raviteja R Guddeti,Alan Wong,Steven Rudick et al.
Raviteja R Guddeti et al.
Introduction: Vascular endothelial growth factor (VEGF) gene therapy is a novel treatment strategy for refractory angina (RA) that works by promoting myocardial neoangiogenesis and collateral circulation formation. XC001 ...
Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer [0.03%]
B7-H3靶向抗体药物偶联物ifinatamab deruxtecan治疗小细胞肺癌的临床进展
Mylène Wespiser,Romane Gille,Maurice Perol
Mylène Wespiser
Introduction: Small cell lung cancer is an aggressive malignancy with limited treatment options and poor prognosis, particularly at extensive stage. While first-line platinum-etoposide chemotherapy combined with anti-PD-L...